Industry

Genentech pays Alector $100 million for Parkinson’s drug rights

Fierce Biotech reported that Genentech will pay Alector $100 million upfront for exclusive rights to a preclinical drug candidate for Parkinson’s disease.

Reported by 2 outlets Tuesday, October 6, 2026

Brain scan images on monitors in an MRI control room
Photo: Public domain, U.S. Navy Medicine

The original reports on this story are listed below.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.